# Revolution Medicines, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Revolution Medicines, Inc.). ## Overview Revolution Medicines, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on precision oncology. It develops small-molecule therapies designed to target RAS-addicted cancers, with its pipeline centered on RAS(ON) inhibitors and related combination approaches. ## Products & services • RAS(ON) inhibitor drug candidates • Precision oncology small-molecule therapeutics • Combination therapy development programs • Clinical-stage cancer biomarker collaborations • Outsourced drug manufacturing and supply - **RAS(ON) Inhibitors** (0%) — Small-molecule therapies designed to inhibit the active, GTP-bound form of RAS in cancer cells. - **Precision Oncology Pipeline** (0%) — Clinical and preclinical oncology programs built around genetic drivers and resistance biology. - **Combination Therapy Development** (0%) — Programs that test RAS-targeted agents with other therapies to improve response and durability. - **Collaboration Revenue** (100%) — Research collaboration arrangements that support discovery and biomarker work. - RAS(ON) inhibitor drug candidates - Precision oncology small-molecule therapeutics - Combination therapy development programs - Clinical-stage cancer biomarker collaborations - Outsourced drug manufacturing and supply ## Customers The company’s direct counterparties are primarily pharmaceutical collaborators, research partners, and contract manufacturers rather than end-market patients. If approved, its future customers would be oncologists, hospitals, cancer centers, and third-party payors that determine access and reimbursement for targeted cancer medicines. - **Research collaborators** (secondary) — Pharmaceutical and biotech partners that support discovery, preclinical work, or biomarker programs. - **Clinical trial sites and investigators** (primary) — Cancer centers and physicians that enroll patients and generate clinical data for pipeline advancement. - **Future oncology prescribers** (primary) — Oncologists who would prescribe approved RAS-targeted therapies in relevant cancer indications. - **Third-party payors** (primary) — Commercial insurers and government programs that determine coverage, pricing, and reimbursement. - Pharmaceutical collaborators funding or supporting research programs - Clinical investigators and cancer centers running trials - Oncologists who would prescribe approved therapies - Hospitals and specialty pharmacies that dispense oncology drugs - Third-party payors that influence coverage and reimbursement ## Geography Revolution Medicines is headquartered in the United States and expects its first commercial launch, if approved, to be in the U.S. before expanding to Europe and Asia. Its development and commercialization model is global in scope, but manufacturing is outsourced to third-party CDMOs and future market access will depend on country-specific reimbursement systems. - Headquartered in the United States - First expected commercial launch would be in the U.S. - Europe and Asia are planned follow-on markets - International reimbursement rules can affect pricing and access - Manufacturing is outsourced to third-party CDMOs ## Strategy The company is building a portfolio of RAS(ON) inhibitors for RAS-addicted cancers and intends to retain meaningful development and commercialization rights. Its strategy combines internal drug discovery with collaborations, biomarker work, and combination-therapy development to improve the odds of clinical differentiation. - **Advance lead RAS(ON) inhibitor programs** (short-term) — Clinical proof of concept is central to validating the platform and creating future product value. - **Build combination and biomarker capabilities** (medium-term) — Combination regimens and biomarker insights can improve response rates and patient selection. - **Prepare for commercialization in major markets** (medium-term) — A direct launch model requires medical, regulatory, manufacturing, and market access readiness. - Advance RAS(ON) inhibitors through clinical development - Use combination regimens to address resistance biology - Retain U.S. and ex-U.S. commercialization rights where possible - Expand biomarker and translational research through collaborations - Rely on CDMOs to scale manufacturing without owning plants ## Risks The business depends on successful clinical development of unproven RAS-targeted therapies, and failure in preclinical or clinical studies would materially impair the platform. As a clinical-stage biotech with no approved products, it also faces substantial financing, regulatory, manufacturing, and reimbursement risk before any commercial revenue can scale. - **Clinical development failure** [critical] — Pipeline value depends on demonstrating safety and efficacy in human trials. - **Scientific uncertainty around direct RAS inhibition** [high] — The target has historically been difficult to drug, so the mechanism may not translate into durable approvals. - **Financing risk** [high] — The company will need substantial capital before product sales can fund operations. - **Reimbursement and pricing pressure** [medium] — Oncology drugs depend on coverage decisions and may face price controls or negotiation. - **Manufacturing and supply dependence** [medium] — All manufacturing is outsourced to CDMOs, creating third-party execution and quality risk. - No approved products, so value depends on clinical success - RAS inhibition is scientifically challenging and unproven - Additional financing may be needed to fund development - Third-party payor coverage and pricing may limit adoption - Outsourced manufacturing creates supply and quality dependence ## Accounting The company’s accounting is dominated by research and development expense recognition, accrued trial/vendor costs, and estimates tied to future royalties and collaboration arrangements. Because it is pre-commercial, small changes in clinical progress, vendor accruals, or fair-value assumptions can materially affect reported results and balance-sheet liabilities. - **Research and development expense accruals** — Can shift quarterly operating loss materially - **Collaboration revenue recognition** — Affects timing and amount of non-product revenue - **Liability related to sale of future royalties** — Can create significant non-cash balance-sheet and P&L volatility - **Prepaid R&D and deferred advance payments** — Affects expense timing across reporting periods - R&D costs are expensed as incurred, affecting period losses - Accrued trial and vendor costs rely on management estimates - Collaboration revenue depends on contract terms and milestones - Future royalty liability requires valuation assumptions - Prepaid R&D and deferred costs affect timing of expense recognition --- *Last updated: 2026-04-29T04:53:36.689061+00:00*